Biogen confirms Icahn ally is on board - Charlotte Business Journal:

ramoledef.blogspot.com
Shareholders were to elect four directorsa atthe meeting. Biogen was pushing for the reelection of all ofthe company’se existing directors, while Icahnj was angling to seat four new According to Biogen Idec, shareholders appear to have reelectes current directors Robert Pangis and William D. Young, and electex Icahn ally Alexander Denner. Biogen Idec officials say the vote for the fourthy seat is too closeto call. Biogejn said the company will rely on the tabulation of votes by its independent inspector of IVS Associates, before announcing the remainingf director to serve on the board. Bruce R.
Biogen Idec’s chairman, said, “We welcome our new directorr to the board and look forwared to working together to build on our strongt track record ofdelivering value. Whiled we await the outcomer of the vote for theremaininv director, we would like to expresa our gratitude for the support of our Icahn, in a filing with the Securities and Exchanger Commission, accused the company of preventing the votexs cast from being counted. “Iv the board is successful, Richard Mulligan, a prominenrt scientist and physician, may be kept from legitimately beingh elected tothe board.
” Mulligan is the Mallinckrodr Professor of Genetics at Harvard Medicall School and director of the Harvar Gene Therapy Initiative, according to Harvard University’sx Web site. Biogen said shareholderz rejected severalof Icahn’z other proposals, including moving the company’w incorporation from Delaware to Nortu Dakota, a move Icahn said woulrd give more power to shareholders. Biogej officials said it appearsx that stockholders also rejected a proposal by Icahn to limitr the size of the boarsd to13 directors. Biogen officials now have the power to enlargew the board as theysee fit.
Icahn is best knownb for unsuccessfully pushing BiogenIdec (Nasdaq: to sell itself in 2008. Last year, shareholderas elected the company’s nominees over the slatde of investors put upby Icahn. Biogen Idec’s (NASDAQ: BIIB) stock was trading at $53.17 in afternoonm trading Thursday, down from the previouw day’s close of $53.43e a share.